Gastrointestinal Cancer News

The FDA granted breakthrough therapy designation to atezolizumab in combination with bevacizumab as a first-line treatment for patients with advanced metastatic hepatocellular carcinoma.

Mailing fecal immunochemical tests directly to patients insured by Medicaid helped improve colorectal cancer screening rates, according to research published in Cancer.

A clinical prediction model that used tumor-site category and D-dimer as the only variables accurately predicted risk for venous thromboembolism among patients with solid cancers seen outside the hospital setting, according to findings published in The Lancet Haematology.

Venous thromboembolism incidence appeared high among patients with solid tumors who had implanted ports, according to study results.

Patients who underwent weekend emergency surgery for colon cancer appeared to have greater mortality and more severe complication rates than patients who underwent surgery on a weekday, according to results of a prospective study.

Chimeric antigen receptor T-cell therapy may be an effective treatment strategy for colorectal cancer, according to study results.

Endoscopic noncardia gastric cancer screening might be cost effective among high-risk ethnicities in the United States, such as Hispanics, blacks and East Asians, despite low prevalence nationwide, according to research published in Gastroenterology.

Patients who survived 8.75 years after being diagnosed with pancreatic adenocarcinoma were more likely to die of other causes than of their cancer, according to a research letter published in JAMA Oncology.

The FDA granted priority review to pembrolizumab for previously treated patients with advanced hepatocellular carcinoma, the agent’s manufacturer announced.

The FDA granted accelerated approval to the combination of nivolumab and low-dose ipilimumab for treatment of microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, according to the agents’ manufacturer.